Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Share-based Compensation of $6.4 million for Q1 2026, up 118.32% year-over-year from $2.9 million in Q1 2025, and up 18.37% quarter-over-quarter from $5.4 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends
Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 118.32% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $23.0 million (up 80.81% YoY), while the FY2025 annual figure was $19.4 million, up 74.03% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.4 million, up from $5.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $6.4 million in Q1 2026, with the low at $150513.2 in Q4 2022.
- The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 733.86% in 2024, then soared 50.32% in 2025.
- Oculis Holding AG's Share-based Compensation stood at $150513.2 in 2022, then surged by 680.47% to $1.2 million in 2023, then soared by 176.17% to $3.2 million in 2024, then jumped by 66.3% to $5.4 million in 2025, then climbed by 18.37% to $6.4 million in 2026.
- Business Quant data shows OCS's Share-based Compensation at $6.4 million in Q1 2026, $5.4 million in Q4 2025, and $5.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | -6.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.38 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | -14.82 Mn |
| Sep 30, 2025 | 14.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | -8.03 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | -2.93 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 156,768.57 |
| Dec 31, 2022 | 150,513.18 |
| Sep 30, 2022 | 200,878.59 |